My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C101P Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 1 mg 295.00
C101P Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 5 mg 995.00
C101P Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 20 mg 2950.00
C100P Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody 1 mg 495.00
Description

C101P: Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Recombinant Human IgG1 Kappa Monoclonal Antibody.
Isotype: Human IgG1 kappa.
Source: The anti-SARS-CoV-2 spike monoclonal antibody sotrovimab biosimilar was produced in the sotrovimab biosimilar CHO cells.
Specificity/Sensitivity: The sotrovimab biosimilar specifically binds to the spike protein of SARS-CoV-2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by sotrovimab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity: >95% by SDS-PAGE under reducing condition.

Shipping: The research grade sotrovimab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is sotrovimab biosimilar research grade? Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2. sotrovimab is a human monoclonal antibody (IgG1κ isotype). sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab. sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. sotrovimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar.

Syd Labs also provides the following research grade anti-SARS-CoV-2 spike antibody biosimilar proteins:
Casirivimab biosimilar, research grade, SARS-CoV-2 spike monoclonal antibody

Related Links

See our Privacy Policy